BACKGROUND: Patient interleukin (IL)-1β and IL-10 responses early in Staphylococcus aureus bacteremia (SaB) are associated with bacteremia duration and mortality. We hypothesized that these responses vary depending on antimicrobial therapy, with particular interest in whether the superiority of β-lactams links to key cytokine pathways. METHODS: Three medical centers included 59 patients with SaB (47 methicillin-resistant S. aureus [MRSA], 12 methicillin-sensitive S. aureus [MSSA]) from 2015-2017. In the first 48 hours, patients were treated with either a β-lactam (n = 24), including oxacillin, cefazolin, or ceftaroline, or a glyco-/lipopeptide (n = 35), that is, vancomycin or daptomycin. Patient sera from days 1, 3, and 7 were assayed for IL-1β and IL-10 by enzyme-linked immunosorbent assay and compared using the Mann-Whitney U test. RESULTS: On presentation, IL-10 was elevated in mortality (P = .008) and persistent bacteremia (P = .034), while no difference occurred in IL-1β. Regarding treatment groups, IL-1β and IL-10 were similar prior to receiving antibiotic. Patients treated with β-lactam had higher IL-1β on days 3 (median +5.6 pg/mL; P = .007) and 7 (+10.9 pg/mL; P = .016). Ex vivo, addition of the IL-1 receptor antagonist anakinra to whole blood reduced staphylococcal killing, supporting an IL-1β functional significance in SaB clearance. β-lactam-treated patients had sharper declines in IL-10 than vancomycin or daptomycin -treated patients over 7 days. CONCLUSIONS: These data underscore the importance of β-lactams for SaB, including consideration that the adjunctive role of β-lactams for MRSA in select patients helps elicit favorable host cytokine responses.
BACKGROUND:Patient interleukin (IL)-1β and IL-10 responses early in Staphylococcus aureus bacteremia (SaB) are associated with bacteremia duration and mortality. We hypothesized that these responses vary depending on antimicrobial therapy, with particular interest in whether the superiority of β-lactams links to key cytokine pathways. METHODS: Three medical centers included 59 patients with SaB (47 methicillin-resistant S. aureus [MRSA], 12 methicillin-sensitive S. aureus [MSSA]) from 2015-2017. In the first 48 hours, patients were treated with either a β-lactam (n = 24), including oxacillin, cefazolin, or ceftaroline, or a glyco-/lipopeptide (n = 35), that is, vancomycin or daptomycin. Patient sera from days 1, 3, and 7 were assayed for IL-1β and IL-10 by enzyme-linked immunosorbent assay and compared using the Mann-Whitney U test. RESULTS: On presentation, IL-10 was elevated in mortality (P = .008) and persistent bacteremia (P = .034), while no difference occurred in IL-1β. Regarding treatment groups, IL-1β and IL-10 were similar prior to receiving antibiotic. Patients treated with β-lactam had higher IL-1β on days 3 (median +5.6 pg/mL; P = .007) and 7 (+10.9 pg/mL; P = .016). Ex vivo, addition of the IL-1 receptor antagonist anakinra to whole blood reduced staphylococcal killing, supporting an IL-1β functional significance in SaB clearance. β-lactam-treated patients had sharper declines in IL-10 than vancomycin or daptomycin -treated patients over 7 days. CONCLUSIONS: These data underscore the importance of β-lactams for SaB, including consideration that the adjunctive role of β-lactams for MRSA in select patients helps elicit favorable host cytokine responses.
Authors: Monique Vogel; Roland P H Schmitz; Stefan Hagel; Mathias W Pletz; Nico Gagelmann; André Scherag; Peter Schlattmann; Frank M Brunkhorst Journal: J Infect Date: 2015-10-09 Impact factor: 6.072
Authors: Chahnaz Kebaier; Robin R Chamberland; Irving C Allen; Xi Gao; Peter M Broglie; Joshua D Hall; Corey Jania; Claire M Doerschuk; Stephen L Tilley; Joseph A Duncan Journal: J Infect Dis Date: 2012-01-25 Impact factor: 5.226
Authors: Benjamin P Howden; Paul D R Johnson; Peter B Ward; Timothy P Stinear; John K Davies Journal: Antimicrob Agents Chemother Date: 2006-09 Impact factor: 5.191
Authors: Catherine Liu; Arnold Bayer; Sara E Cosgrove; Robert S Daum; Scott K Fridkin; Rachel J Gorwitz; Sheldon L Kaplan; Adolf W Karchmer; Donald P Levine; Barbara E Murray; Michael J Rybak; David A Talan; Henry F Chambers Journal: Clin Infect Dis Date: 2011-02-01 Impact factor: 9.079
Authors: D R Cameron; Y-H Lin; S Trouillet-Assant; V Tafani; X Kostoulias; E Mouhtouris; N Skinner; K Visvanathan; S L Baines; B Howden; I R Monk; F Laurent; T P Stinear; B P Howden; A Y Peleg Journal: Clin Microbiol Infect Date: 2017-04-07 Impact factor: 8.067
Authors: Vance G Fowler; Maren K Olsen; G Ralph Corey; Christopher W Woods; Christopher H Cabell; L Barth Reller; Allen C Cheng; Tara Dudley; Eugene Z Oddone Journal: Arch Intern Med Date: 2003-09-22
Authors: Sara E Cosgrove; George Sakoulas; Eli N Perencevich; Mitchell J Schwaber; Adolf W Karchmer; Yehuda Carmeli Journal: Clin Infect Dis Date: 2002-12-13 Impact factor: 9.079
Authors: George Sakoulas; Pamela A Moise; Anthony M Casapao; Poochit Nonejuie; Joshua Olson; Cheryl Y M Okumura; Michael J Rybak; Ravina Kullar; Abhay Dhand; Warren E Rose; Debra A Goff; Adam M Bressler; Yuman Lee; Joseph Pogliano; Scott Johns; Glenn W Kaatz; John R Ebright; Victor Nizet Journal: Clin Ther Date: 2014-07-10 Impact factor: 3.393
Authors: Benjamin P Howden; Danielle J Smith; Ashley Mansell; Paul D R Johnson; Peter B Ward; Timothy P Stinear; John K Davies Journal: BMC Microbiol Date: 2008-02-27 Impact factor: 3.605
Authors: Arnold S Bayer; Selvi C Ersoy; Warren E Rose; Ana M Bienvenida; Yan Q Xiong; Henry F Chambers Journal: Antimicrob Agents Chemother Date: 2020-02-21 Impact factor: 5.191
Authors: Martina Fabris; Fabio Del Ben; Emanuela Sozio; Antonio Paolo Beltrami; Adriana Cifù; Giacomo Bertolino; Federica Caponnetto; Marco Cotrufo; Carlo Tascini; Francesco Curcio Journal: Int J Mol Sci Date: 2022-04-27 Impact factor: 6.208
Authors: Michael J Salazar; Henrique Machado; Nicholas A Dillon; Hannah Tsunemoto; Richard Szubin; Samira Dahesh; Joseph Pogliano; George Sakoulas; Bernhard O Palsson; Victor Nizet; Adam M Feist Journal: mSystems Date: 2020-03-31 Impact factor: 6.496